E. Kelley

Once-daily versus twice-daily levobunolol (0.5%) therapy. A crossover study.

A. Coleman, J. Tielsch, A. Robin, 1992, Ophthalmology.

Ocular hypotensive efficacy of 0.25% levobunolol instilled once daily.

G. Novack, T. Wandel, E. Kelley, 1988, Ophthalmology.

Plasma levobunolol levels following topical administration with reference to systemic side effects.

G. Novack, D. Tang-Liu, E. Kelley, 1987, Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde.

Brimonidine tartrate: a one-month dose response study.

J. Schuman, A. Robin, R. Derick, 1997, Ophthalmology.

Prophylactic treatment of intraocular pressure elevations after neodymium: YAG laser posterior capsulotomies and extracapsular cataract extractions with levobunolol.

G. Novack, E. Kelley, D. Silverstone, 1988, Ophthalmology.

A multicenter evaluation of levobunolol (Vistagan) in Germany.

G. Novack, J. Lue, E. Kelley, 1988, Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde.

A double-masked comparison of betaxolol and dipivefrin for the treatment of increased intraocular pressure.

R. Leblanc, D. Albracht, K. Stern, 1993, American journal of ophthalmology.

Evaluation of once-daily levobunolol 0.25% and timolol 0.25% therapy for increased intraocular pressure.

D Silverstone, T. Zimmerman, T Zimmerman, 1991, American journal of ophthalmology.

Brimonidine and pupillary diameter: Authors’ reply

J. Schuman, A. Robin, R. Derick, 1998 .

A comparison of the ocular hypotensive efficacy of twice-daily 0.25% levobunolol to 0.5% timolol in patients previously treated with 0.5% timolol.

A. Crandall, W. C. Stewart, C. Ostrov, 1992, Journal of glaucoma.